Ascelia Pharma AB (OSTO:ACE) Beginning Cash Position: kr49.86 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ACE Ascelia Pharma AB OSTO:ACE
28 GF Score
Price kr0.49
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Beginning Cash Position?

Ascelia Pharma AB OSTO:ACE -3.24% 28 Beginning Cash Position is kr49.86 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's Beginning Cash Position for the quarter that ended in Mar. 2026 was kr49.86 Mil.

Ascelia Pharma AB's quarterly Beginning Cash Position increased from Sep. 2025 (kr60.44 Mil) to Dec. 2025 (kr72.28 Mil) but then declined from Dec. 2025 (kr72.28 Mil) to Mar. 2026 (kr49.86 Mil).

Ascelia Pharma AB's annual Beginning Cash Position declined from Dec. 2023 (kr149.55 Mil) to Dec. 2024 (kr21.86 Mil) but then increased from Dec. 2024 (kr21.86 Mil) to Dec. 2025 (kr75.26 Mil).

Ascelia Pharma AB Beginning Cash Position Related Terms

Ascelia Pharma AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Beginning Cash Position Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 184.69 261.60 149.55 21.86 75.26

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.26 57.30 60.44 72.28 49.86
OSTO:ACE
28GF Score
Ascelia Pharma AB OSTO:ACE
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr49.86 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Beginning Cash Position of kr49.86 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Beginning Cash Position too high?
Ascelia Pharma AB's current Beginning Cash Position is kr49.86 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Beginning Cash Position compare to VRTX and REGN?
Ascelia Pharma AB's Beginning Cash Position of kr49.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Beginning Cash Position is kr49.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Beginning Cash Position of kr49.86 Mil. The current Beginning Cash Position is kr49.86 Mil. Ascelia Pharma AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Beginning Cash Position is kr49.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
28GF Score

Get the complete analysis for OSTO:ACE

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.49
Price